Cencora, Inc. (COR)

NYSE: COR · USD

$324

-1.24 (-0.4%)· Recorded snapshot

Englische QuelleDE

Englische Quelle wird angezeigt, während wir übersetzen

Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.

StockMarketAgent Research · Analyzed 2026-10-22

Our latest published analysis: COR rated Hold

Cencora, Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$329 / share

Potential value

$487 / share

Upside to FV

-3.5%

from $324

Moat

7.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$65.0B
Revenue (ttm)	332.8B
Net income (ttm)	2.6B
EPS (ttm)	$13.5
Shares out	190.8M
P/E (trailing)	24.1x
P/E (forward)	15.7x
Dividend	$2.40 (0.74%)
Volume	827,715
Beta	0.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 332.8B
Net income (ttm): 2.6B
EPS (ttm): $13.5
P/E (trailing): 24.1x
P/E (forward): 15.7x
Market cap: $65.0B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-09-30	2023-09-30	2024-09-30	2025-09-30	2026-09-30	Trend
Revenue	$238.59B	$262.17B	$293.96B	$321.33B	—	+10.4%
Gross profit	$8.30B	$8.96B	$9.91B	$11.48B	—	+11.4%
Operating income	$2.37B	$2.34B	$2.18B	$2.63B	—	+3.6%
Net income	$1.70B	$1.75B	$1.51B	$1.55B	—	-2.9%
EPS (diluted)	$8.04	$8.53	$7.53	$7.96	$13.31	+13.4%
EBITDA	$3.12B	$3.42B	$3.37B	$3.75B	—	+6.2%
R&D	—	—	—	—	—	—
SG&A	$4.85B	$5.31B	$5.66B	$6.49B	—	+10.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	Verkaufen
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	Verkaufen
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	Starker Kauf
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Verkaufen
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Reduzieren
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Reduzieren

Base and Bull scenarios

Bull20%

Price target

$487.41

+43.2% from spot

Specialty pharmaceutical distribution and oncology MSO capabilities accelerate following the integration of American Oncology Network. Top-line revenue compounds at 7.5% to 8.0%, gross margin expands above 3.7%, and operating margin expands toward peer levels of 1.35%. Robust free cash flow accelerates share retirements well beyond the baseline.

Accelerated revenue growth supported by specialty distribution tailwinds
Operating margin expansion driven by oncology practice management services
Accelerated diluted share count reduction through continuous share repurchases

Base60%

Price target

$328.59

-3.5% from spot

Cencora compounds at steady mid-single-digit rates in line with the house schedule, with FY2027 revenue reaching $351.85B and adjusted EPS reaching $19.80. Operating margin normalizes along the 1.22% to 1.30% glide path, while share repurchases reduce diluted share count by 1.5% annually, supporting a fair value of $328.59.

Steady revenue growth in line with historical prescription volume expansion
Stable operating margin progression reflecting wholesale triopoly pricing discipline
Terminal exit multiple consistent with historical distributor valuations
Cost of equity of 7.61%

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($328.59). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
6.6%	$356	$364	$373	$384	$395
7.1%	$335	$342	$349	$357	$366
7.6%	$318	$323	$329	$335	$342
8.1%	$303	$307	$312	$317	$322
8.6%	$289	$293	$297	$301	$306

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E15.7

P25 n/aP50 n/aP75 n/a

Trailing P/E25.5

P25 n/aP50 n/aP75 n/a

ROE96.9

P25 n/aP50 n/aP75 n/a

ROIC20.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All COR indicators

Market & fundamental data

Available fields

287

Groups with data

Currency

USD

Showing 287 of 287 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001140859
Company name	Cencora, Inc.
Country	United States
Country code	US
CUSIP number	03073E105
Earnings date	2026-11-04
Earnings time	bmo
Employees	51,000
Employees change	5,000
Employees growth	10.87%
Enterprise value	$73.5B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	September
Founded	2001
In index	SP500
Industry	Medical Distribution
Is primary listing	Yes
Is SPAC	No
ISIN number	US03073E1055
Last 10-K release date	2025-11-25
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split date	2009-06-16
Last stock split type	Forward
Market cap	$61.9B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$324.14
Price currency	USD
Sector	Healthcare
SIC code	5122
Stock price date	2026-10-28
Symbol	COR
U.S. state	Pennsylvania
Website	https://www.cencora.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	18.9x
Average P/E ratio (10Y)	22.13x
Average P/E ratio (3Y)	28.29x
Average P/E ratio (5Y)	24.33x
Earnings yield	4.15%
EV/Earnings	28.13x
EV/EBIT	16.44x
EV/EBITDA	13.31x
EV/FCF	18.18x
EV/Sales	0.22x
FCF / EV yield	5.5%
FCF yield	6.53%
Forward EV/Sales	0.21x
Forward P/E	16.8x
Forward P/S	0.18x
Graham number	69.58774
Graham upside	-78.65%
Industry forward P/E	19.16x
Industry P/E	27.41x
Lynch fair value	$212.95
Lynch upside	-34.65%
P/(FCF - SBC) ratio	15.9x
P/(OCF - SBC) ratio	13.31x
P/B ratio	20.35x
P/E ratio	24.08x
P/FCF ratio	15.32x
P/OCF ratio	12.9x
P/S ratio	0.19x
PEG ratio	1.73x
Price/EBITDA ratio	11.21x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	1.35%
EBITDA margin	1.67%
Effective tax rate	26.82%
FCF margin	1.22%
Gross margin	3.96%
Operating margin	1.35%
Pretax margin	1.08%
Profit margin	0.79%
Profit per employee	$51,467
Profitable quarters	3
Profitable years	5
Revenue per employee	$6.5M
ROA	3.56%
ROA (5Y)	2.99%
ROCE	18.25%
ROE	96.87%
ROIC	20.95%
ROIC (5Y)	47.06%
SBC / revenue	0.04%
Tax / revenue	0.29%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	39.11%
EPS growth (Q)	11.93%
EPS growth (QoQ)	-53.1%
EPS growth 10Y	6.18%
EPS growth 3Y	18.02%
EPS growth quarters	3
EPS growth years	1
FCF growth	255.65%
FCF growth (QoQ)	106.99%
FCF growth 3Y	13.29%
FCF growth 5Y	9.63%
Gross profit growth	22.92%
Gross profit growth (Q)	24.3%
Gross profit growth 3Y	15.64%
Gross profit growth 5Y	16.8%
Net income growth	38.35%
Net income growth (Q)	11.07%
Net income growth (QoQ)	-53.48%
Net income growth 3Y	15.82%
Net income growth quarters	3
Net income growth years	1
OCF growth	176.74%
OCF growth (Q)	2,329.41%
OCF growth (QoQ)	98.27%
OCF growth 10Y	4.91%
OCF growth 3Y	14.06%
OCF growth 5Y	10.28%
Operating income growth	30.32%
Operating income growth (Q)	23.65%
Operating income growth 3Y	22.48%
Operating income growth 5Y	11.75%
Revenue growth	5.09%
Revenue growth (Q)	5.07%
Revenue growth (QoQ)	8.17%
Revenue growth 10Y	8.68%
Revenue growth 3Y	9.36%
Revenue growth 5Y	10.25%
Revenue growth quarters	56
Revenue growth years	13

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-760.8M
Depreciation and amortization	$1.1B
EBIT	$4.5B
EBITDA	$5.5B
EPS	$13.46
FCF per share	$21.28
Financing cash flow	$1.6B
Free cash flow	$4.1B
Free cash flow minus SBC	$3.9B
Gross profit	$13.2B
Income taxes	$967.3M
Investing cash flow	$-5.7B
Net borrowing	$3.1B
Net cash flow	$589.6M
Net income	$2.6B
Operating cash flow minus SBC	$4.7B
Operating income	$4.5B
Revenue	$332.8B
Stock-based compensation	$148.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.7
Book value per share	$15.99
Debt / EBITDA	2.44
Debt / equity	4.47
Debt / FCF	3.56
Goodwill	$16.5B
Interest coverage	8.78
Long-term assets	$28.5B
Long-term liabilities	$21.4B
Net cash (debt)	$-11.6B
Net cash / market cap	-18.73%
Net debt / EBITDA	2.1
Net debt / equity	3.6
Net debt / FCF	2.87
Piotroski F-Score	6
Property, plant and equipment	$2.8B
Shareholders' equity	$3.2B
Tangible book value	$-19.4B
Tangible book value per share	$-101.64
Total assets	$83.8B
Total cash	$2.8B
Total debt	$14.5B
Total liabilities	$80.6B
WACC	6.53%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	4.22
Current assets	$55.3B
Current liabilities	$59.2B
Current ratio	0.93
Inventory turnover	15.53
Net working capital	$-6B
Quick ratio	0.48
Working capital	$-3.9B
Working capital turnover	-73.9

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.46%
Dividend growth	9.09%
Dividend growth (10Y)	5.84%
Dividend growth (3Y)	7.35%
Dividend growth (5Y)	6.4%
Dividend growth years	21
Dividend payment date	2026-08-31
Dividend payment years	26
Dividend payout frequency	Quarterly
Dividend per share	$2.40
Dividend yield	0.74%
Ex-dividend date	2026-08-14
FCF payout ratio	11.28%
Last dividend	$0.60
Payout ratio	17.83%
Shareholder yield	1.19%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	308.11%
10Y return CAGR	18.47%
10Y total return	444.57%
150-day SMA	$305.27
15Y price change	682%
15Y return CAGR	17.48%
15Y total return	1,021.19%
1D price change	-0.38%
1M price change	5.71%
1M total return	5.71%
1W price change	-5.48%
1W total return	-5.48%
1Y price change	-3.45%
1Y return CAGR	-2.72%
1Y total return	-2.72%
20-day SMA	$327.96
200-day SMA	$317.26
20Y price change	1,288.62%
20Y return CAGR	16.58%
20Y total return	2,048.39%
3M price change	4.27%
3M total return	4.47%
3Y price change	72.91%
3Y return CAGR	21.03%
3Y total return	77.3%
50-day SMA	$322.79
50-day SMA vs 200-day SMA	50over200
52-week high	$377.54
52-week high date	2025-11-25
52-week low	$244.82
52-week low date	2026-05-06
5Y price change	171.39%
5Y return CAGR	23.6%
5Y total return	188.41%
6M price change	4.61%
6M total return	5.05%
All-time high	$377.54
All-time high date	2025-11-25
All-time low	$2.47
All-time low date	1995-08-09
Average true range (ATR)	$6.94
Average volume	1.1M
Beta (1Y)	-0.03
Beta (2Y)	0.08
Beta (5Y)	0.58
Change from 52-week high	-14.14%
Change from 52-week low	32.4%
Change from all-time high	-14.06%
Change from all-time low	13,040.95%
Change from open	0.45%
Day's gap	-0.82%
Dollar volume	$268.3M
High price	$327.38
Low price	$322.39
Monthly RSI	56.58
Open price	$322.70
Position in 52-week range	35.07%
Premarket change	-0.42%
Premarket close	$325.37
Premarket price	$324.00
Premarket volume	518
Previous close	$325.37
Price vs 150-day SMA	6.28%
Price vs 20-day SMA	-1.07%
Price vs 200-day SMA	2.27%
Price vs 50-day SMA	0.51%
Relative volume	0.72
RSI	47.37
Sharpe ratio	-0.05
Sharpe ratio (3Y)	0.74
Sharpe ratio (5Y)	0.85
Sortino ratio	0.09
Sortino ratio (3Y)	1.21
Sortino ratio (5Y)	1.4
Volume	827.7K
Weekly RSI	53.45
YTD price change	-3.94%
YTD total return	-3.37%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	180.3M
Float percentage	94.46%
Shares change (QoQ)	-0.74%
Shares change (YoY)	-0.46%
Shares held by insiders	0.38%
Shares held by institutions	97.28%
Shares outstanding	190.8M
Short % of float	2.17%
Short % of shares	2.05%
Short ratio	3 days

Deeper analysis on COR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this COR report

What is the latest published COR stock rating?

Cencora, Inc. is shown with Hold in the latest published report, analyzed 2026-10-22. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full COR analysis?

The full latest published report, analyzed 2026-10-22, lives at /stocks/COR/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for COR?

The latest published report analyzed 2026-10-22 gives COR a fair value of USD 329 and a potential value of USD 487. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the COR page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-22). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldCOR · Fair value $329-3.5%

Read full analysis →

Cencora, Inc. (COR)

Our latest published analysis: COR rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · COR

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All COR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on COR

Frequently asked questions

Ratingverlauf

Category	Score	Reading
Valuation	4.5
Management	8.5
Balance Sheet	1.5
Profitability	7.0
Revenue Growth	6.0
Risk Assessment	3.5
Competitive Moat	7.5
Earnings Quality	8.0
Capital Efficiency	6.5